Exact Mass: 686.3877

Exact Mass Matches: 686.3877

Found 42 metabolites which its exact mass value is equals to given mass value 686.3877, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

PA(12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

[(2R)-3-(dodecanoyloxy)-2-{[(5R,6R,7Z,9Z,11E,13E,15S,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C35H59O11P (686.3795)


PA(12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5S,6S,7Z,9Z,11E,13E,15R,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C35H59O11P (686.3795)


PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/12:0), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

[(2R)-3-[(10-methylundecanoyl)oxy]-2-{[(5R,6R,7Z,9Z,11E,13E,15S,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C35H59O11P (686.3795)


PA(i-12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-12:0)

[(2R)-2-[(10-methylundecanoyl)oxy]-3-{[(5S,6S,7Z,9Z,11E,13E,15R,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C35H59O11P (686.3795)


PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-12:0), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

telocinobufagin 3-suberoyl-L-glutamine ester

telocinobufagin 3-suberoyl-L-glutamine ester

C37H54N2O10 (686.3778)


   
   

Gamabufotalin-3-adipoylargininester

Gamabufotalin-3-adipoylargininester

C36H54N4O9 (686.3891)


   
   

Hydroxysaquinavir M3

Hydroxysaquinavir M3

C38H50N6O6 (686.3792)


   

Hydroxysaquinavir M2

Hydroxysaquinavir M2

C38H50N6O6 (686.3792)


   

Hydroxysaquinavir M7

Hydroxysaquinavir M7

C38H50N6O6 (686.3792)


   

PA(12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

PA(12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C35H59O11P (686.3795)


   

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/12:0)

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/12:0)

C35H59O11P (686.3795)


   

PA(i-12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

PA(i-12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C35H59O11P (686.3795)


   

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-12:0)

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-12:0)

C35H59O11P (686.3795)


   

N-(2-aminophenyl)-4-[[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-9-[[3-(4-morpholinyl)-1-oxopropyl]amino]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl-methylamino]methyl]benzamide

N-(2-aminophenyl)-4-[[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-9-[[3-(4-morpholinyl)-1-oxopropyl]amino]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl-methylamino]methyl]benzamide

C38H50N6O6 (686.3792)


   
   

[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-phosphonooxypropyl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-phosphonooxypropyl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C39H59O8P (686.3947)


   

[1-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

[1-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C39H59O8P (686.3947)


   

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoate

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoate

C39H59O8P (686.3947)


   

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

C39H59O8P (686.3947)


   

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C39H59O8P (686.3947)


   
   

PA 20:2/12:3;O3

PA 20:2/12:3;O3

C35H59O11P (686.3795)


   

PA 20:3/12:2;O3

PA 20:3/12:2;O3

C35H59O11P (686.3795)


   
   
   

PG P-16:1/13:4;O2

PG P-16:1/13:4;O2

C35H59O11P (686.3795)


   

PG P-20:1/9:4;O2

PG P-20:1/9:4;O2

C35H59O11P (686.3795)


   
   
   
   
   
   
   

ST 29:1;O7;GlcA

ST 29:1;O7;GlcA

C35H58O13 (686.3877)


   

ST 29:2;O8;Hex

ST 29:2;O8;Hex

C35H58O13 (686.3877)


   

(1r,2e,4e,6e,8e,10s,11r,14r,15s,17s,19s,21r,23r,25r,26s,27s,28r)-10,15,17,19,21,23,25,26,27-nonahydroxy-14-[(1r)-1-hydroxyhexyl]-11,28-dimethyl-12,29-dioxabicyclo[26.1.0]nonacosa-2,4,6,8-tetraen-13-one

(1r,2e,4e,6e,8e,10s,11r,14r,15s,17s,19s,21r,23r,25r,26s,27s,28r)-10,15,17,19,21,23,25,26,27-nonahydroxy-14-[(1r)-1-hydroxyhexyl]-11,28-dimethyl-12,29-dioxabicyclo[26.1.0]nonacosa-2,4,6,8-tetraen-13-one

C35H58O13 (686.3877)


   

2-[(8-{[3a,5a-dihydroxy-9a,11a-dimethyl-1-(6-oxopyran-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-1-hydroxy-8-oxooctylidene)amino]-4-(c-hydroxycarbonimidoyl)butanoic acid

2-[(8-{[3a,5a-dihydroxy-9a,11a-dimethyl-1-(6-oxopyran-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-1-hydroxy-8-oxooctylidene)amino]-4-(c-hydroxycarbonimidoyl)butanoic acid

C37H54N2O10 (686.3778)


   

(2s)-2-[(8-{[(1r,3as,3br,5as,7s,9ar,9bs,11ar)-3a,5a-dihydroxy-9a,11a-dimethyl-1-(6-oxopyran-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-1-hydroxy-8-oxooctylidene)amino]-4-(c-hydroxycarbonimidoyl)butanoic acid

(2s)-2-[(8-{[(1r,3as,3br,5as,7s,9ar,9bs,11ar)-3a,5a-dihydroxy-9a,11a-dimethyl-1-(6-oxopyran-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-1-hydroxy-8-oxooctylidene)amino]-4-(c-hydroxycarbonimidoyl)butanoic acid

C37H54N2O10 (686.3778)


   

(1s,2e,4e,6e,8e,10s,11r,14r,15s,17s,19s,21r,23r,25r,26s,27r,28s)-10,15,17,19,21,23,25,26,27-nonahydroxy-14-[(1r)-1-hydroxyhexyl]-11,28-dimethyl-12,29-dioxabicyclo[26.1.0]nonacosa-2,4,6,8-tetraen-13-one

(1s,2e,4e,6e,8e,10s,11r,14r,15s,17s,19s,21r,23r,25r,26s,27r,28s)-10,15,17,19,21,23,25,26,27-nonahydroxy-14-[(1r)-1-hydroxyhexyl]-11,28-dimethyl-12,29-dioxabicyclo[26.1.0]nonacosa-2,4,6,8-tetraen-13-one

C35H58O13 (686.3877)


   

10,15,17,19,21,23,25,26,27-nonahydroxy-14-(1-hydroxyhexyl)-11,28-dimethyl-12,29-dioxabicyclo[26.1.0]nonacosa-2,4,6,8-tetraen-13-one

10,15,17,19,21,23,25,26,27-nonahydroxy-14-(1-hydroxyhexyl)-11,28-dimethyl-12,29-dioxabicyclo[26.1.0]nonacosa-2,4,6,8-tetraen-13-one

C35H58O13 (686.3877)